Apimeds Pharmaceuticals US (APUS) Net Cash Flow (2024 - 2025)

Apimeds Pharmaceuticals US (APUS) posted Net Cash Flow of -$5.3 million for Q4 2025, down 205.94% on a QoQ basis from -$1.7 million in Q3 2025, and down 23043.98% year-over-year from N/an in Q4 2024.

Apimeds Pharmaceuticals US (APUS) Net Cash Flow (2024 - 2025) Analysis & Trends

Apimeds Pharmaceuticals US's Net Cash Flow history runs 2 years deep, the most recent figure standing at -$5.3 million for Q4 2025.

  • Quarterly Net Cash Flow fell 23043.98% year-over-year to -$5.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (up 424.75% YoY) and the FY2025 annual result came in at $1.6 million, up 501.25% from the prior year.
  • Net Cash Flow was -$5.3 million for Q4 2025 at Apimeds Pharmaceuticals US, down from -$1.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $8.5 million in Q2 2025 and bottomed at -$5.3 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Cash Flow (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - -
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 202.00 Mn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn -526.00 Mn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 711.50 Mn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn -277.40 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 461.90 Mn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn -446.50 Mn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn -112.00 Mn
10 Apimeds Pharmaceuticals US 8.17 Mn 8.17 Mn - -5.35 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 -5.35 Mn
Dec 31, 2025 -5.35 Mn
Sep 30, 2025 -1.75 Mn
Sep 30, 2025 -1.75 Mn
Jun 30, 2025 8.50 Mn
Jun 30, 2025 8.50 Mn
Mar 31, 2025 246,887.00
Mar 31, 2025 246,887.00
Dec 31, 2024 -23,116.00
Dec 31, 2024 -23,116.00
Sep 30, 2024 -36,755.00
Sep 30, 2024 -36,755.00
Jun 30, 2024 -184,055.00
Jun 30, 2024 -184,055.00
Mar 31, 2024 -263,100.00
Mar 31, 2024 -263,100.00